Geode Capital Management LLC Decreases Stock Holdings in Immuneering Co. (NASDAQ:IMRX)

Geode Capital Management LLC reduced its holdings in shares of Immuneering Co. (NASDAQ:IMRX) by 5.5% during the third quarter, HoldingsChannel.com reports. The fund owned 209,641 shares of the company’s stock after selling 12,160 shares during the quarter. Geode Capital Management LLC’s holdings in Immuneering were worth $522,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. XTX Topco Ltd increased its position in shares of Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after purchasing an additional 9,274 shares during the last quarter. HighTower Advisors LLC grew its position in Immuneering by 21.4% during the third quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after buying an additional 9,400 shares during the period. Corsair Capital Management L.P. purchased a new stake in Immuneering during the third quarter worth about $25,000. Vontobel Holding Ltd. bought a new stake in Immuneering in the third quarter worth about $25,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Immuneering in the second quarter worth about $44,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Trading Up 3.5 %

Shares of IMRX stock opened at $2.07 on Friday. The firm’s 50 day moving average is $2.05 and its 200 day moving average is $1.78. The stock has a market capitalization of $64.27 million, a P/E ratio of -1.05 and a beta of -0.34. Immuneering Co. has a 12 month low of $1.00 and a 12 month high of $7.68.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Chardan Capital restated a “buy” rating and set a $13.00 price target on shares of Immuneering in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $15.00 price objective on shares of Immuneering in a report on Tuesday, January 7th. Finally, Morgan Stanley downgraded Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $12.80.

Immuneering Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.